SCHEMBL8401277

SCHEMBL8401277

COC(=O)c1ccc(/C(N)=N/O)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.50
MAPT P10636 4/20 0.50
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 2/20 0.50
ALDH1A1 P00352 2/20 0.50
GLA P06280 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
RECQL P46063 1/20 0.47
LMNA P02545 1/20 0.45
GFER P55789 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TDP1 Q9NUW8 1/20 0.42
ABL1 P00519 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6116181 1.00 GAA (0.50) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL6116186 1.00 GAA (0.50) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL20184057 0.89 KMT2A (0.48) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL20184054 0.89 KMT2A (0.48) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL2471431 0.87 KDM4E (0.54) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL2471433 0.87 KDM4E (0.54) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL9968899 0.84 RAB9A (0.51) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL2773603 0.84 RECQL (0.56) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL2773601 0.84 RECQL (0.56) GAAMAPTKDM4EHSD17B10HPGD
SCHEMBL406864 0.84 KDM4E (0.47) GAAMAPTKDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110337440-B Compounds useful for inhibition of ROR-gamma-t 伊莱利利公司 2021-08-03 CN disclosed
US-11008336-B2 Compounds useful for inhibiting RORγt ELI LILLY AND COMPANY (US) 2021-05-18 US disclosed
US-11008336-B2 Compounds useful for inhibiting RORγt ELI LILLY AND COMPANY (US) 2021-05-18 US disclosed
EP-3589638-B1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T LILLY CO ELI (US) 2021-04-07 EP disclosed
EP-3589638-B1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T LILLY CO ELI (US) 2021-04-07 EP disclosed
US-20200048279-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T ELI LILLY AND COMPANY 2020-02-13 US disclosed
US-20200048279-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T ELI LILLY AND COMPANY 2020-02-13 US disclosed
WO-2018160550-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T ELI LILLY AND COMPANY (US) 2018-09-07 WO disclosed
US-20170327489-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists KING'S COLLEGE LONDON (GB) 2017-11-16 US disclosed
US-9790213-B2 Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2017-10-17 US disclosed
WO-2016097004-A1 BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS KING'S COLLEGE LONDON (GB) 2016-06-23 WO disclosed
WO-2015110369-A1 IMIDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2015-07-30 WO disclosed
WO-2015110369-A1 IMIDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2015-07-30 WO disclosed
EP-2463279-B1 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity DAIICHI SANKYO CO LTD (JP) 2014-02-12 EP disclosed
US-8557802-B2 Amide derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-10-15 US disclosed
US-8557802-B2 Amide derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-10-15 US disclosed
EP-2463279-A1 AMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-06-13 EP disclosed
US-20120129832-A1 AMIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-24 US disclosed
US-20120129832-A1 AMIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-24 US disclosed
WO-2011016469-A1 AMIDE DERIVATIVE 第一三共株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129832-A1 AMIDE DERIVATIVE SLC5A1, SLC5A2, SLC2A1 GAA 200/4885MAPT 3667/4885KDM4E 1909/4885
US-20170327489-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists RARB, RARA, RXRB GAA 2906/4885MAPT 2263/4885KDM4E 3575/4885
US-11008336-B2 Compounds useful for inhibiting RORγt RORB, RORC, RORA GAA 1756/4885MAPT 1598/4885KDM4E 1077/4885
US-20200048279-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T RORC, RORB, RORA GAA 1080/4885MAPT 2222/4885KDM4E 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.